期刊文献+

“新药研制与报批”教学改革的探索和实践

Exploration and Practice on the Teaching Reform of the Course of “New Drug Development and Approval”
下载PDF
导出
摘要 “新药研制与报批”是一门高度理论联系实际、技术飞速更新的多学科交叉课程,需要紧跟制药行业的变化,及时进行教学思路与方法的革新,不断探索全新的教学内容与模式。为提升学生的综合认知、职业技能和创新思维,从全新教学内容的设计、教学方法的改进和全新评价体系的探索三个方面进行思考,提出以新药研制的经典案例为基础,重新设计教学内容,引入以学生为主体的案例式和PBL教学法,采用答辩与情景模拟相结合的考核方式,期望对当前的“新药研制与报批”类课程的教学改革提供一些借鉴意义。 The development of new drugs is a multidisciplinary interdisciplinary course with a high degree of integration of theory with practice and rapid technological updating. It is necessary to keep up with changes in the pharmaceutical industry, innovate teaching ideas and methods in a timely manner, and constantly explore new teaching content and models. In order to improve students’ comprehensive cognition, vocational skills and innovative thinking, this paper considers the design of new teaching content, the improvement of teaching methods and the exploration of new evaluation system, and proposes to re-design teaching based on the classic cases of new drug development. It introduces the case-based and PBL teaching method with students as the main body, adopts the assessment method combining defense and scenario simulation, and hopes to provide some reference for the current teaching reform of new drug development and approval courses.
作者 陈瑶 裴玉琼 CHEN Yao;PEI Yu-qiong(School of Pharmacy,Nanjing University of Chinese Medicine,Nanjing,Jiangsu 210023,China)
出处 《教育教学论坛》 2022年第49期54-57,共4页 Education And Teaching Forum
基金 2019年度江苏省教育厅“高校‘青蓝工程’培养对象--优秀青年骨干教师”(苏教师函[2018]42号) 2020年度南京中医药大学药学院高等教育教改研究课题“中药学专业以项目式学习为核心的创新创业教育教学模式的实践与探索”(2020YB003) 2021年度南京中医药大学本科课程思政精品课程“新药研制与报批”(2001KCSZ002)。
关键词 新药研制与报批 教学改革 案例式教学 PBL教学法 New Drug Development and Approval teaching reform case-based teaching PBL teaching method
  • 相关文献

参考文献7

二级参考文献53

  • 1史丽娟,宋光耀.非酒精性脂肪肝中肝脂沉积的机制研究进展[J].生理科学进展,2013,44(6):415-419. 被引量:14
  • 2Chiba K,Adachi K.Discovery of fingolimod,the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis[J].Future Med Chem,2012,4(6):771-781.
  • 3Lugaresi A,di Ioia M,Travaglini D,et al.Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis[J].Neuropsychiatr Dis Treat,2013,9:893-914.
  • 4Giovannoni G,Comi G,Cook S,et al.A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis[J].N Engl J Med,2O10,362(5):416-426.
  • 5Wegner C,Stadelmann C,Pfrtner R,et al.Laquinimod in terfereswith migratory capacity of T cells and reduces IL-17 levels,inflam-matory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis[J].J Neuroimmunol,2010,227(1-2):133-143.
  • 6Sheridan C.Third oral MS drug wins FDA nod[J].Nat Biotechnol,2013,31(5):373.
  • 7Linker RA,Lee DH,Ryan S,et al.Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway[J].Brain,2011,134(Pt 3):678-692.
  • 8Scannevin RH,Chollate S,Jung MY,et al.Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor(erythroid-derived 2)-like 2 pathway[J].J Pharmacol Exp Ther,2012,341(1):274-284.
  • 9Lee DH,Gold R,Linker RA.Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases:therapeutic modulation via fumaric acid esters[J].Int J Mol Sci,2012,13(9):11783-11803.
  • 10Albrecht P,Bouchachia I,Goebels N,et al.Effects of dimethyl fumarate on neuroprotection and immunomodulation[J].J Neuroinflammation,2012,9:163.

共引文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部